{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:10:23Z","timestamp":1761894623725},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mantle cell lymphoma (MCL) remains one of the more challenging sub-types of non-Hodgkin lymphoma. This entity, which is only approximately 10 years old, is characterized by response to many different chemotherapy regimens, though the duration of those responses remains often times quite short. Retreatment with second and third line combination regimens results in shorter and shorter durations of response, with the rapid emergence of a very drug-resistant phenotype. Despite these often frustrating clinical features, there is now a lot of new hope in managing patients with MCL. New insights into the molecular pathogenesis of MCL has revealed a plethora of new potential targets, while our continued efforts in novel targeted drug development has produced a host of agents that are already helping patients with this challenging disease. The use of proteasome inhibitors, for example, represents one example of a new strategy that has offered new hope for patients, and new opportunities for the physician treating this disease. In this review, we will put this biology into perspective, and describe how new revelations in MCL pathogenesis are leading to the identification of many exciting new drugs with promising activity.<\/jats:p>","DOI":"10.1182\/asheducation-2007.1.270","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T18:08:40Z","timestamp":1195236520000},"page":"270-276","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Mantle Cell Lymphoma: Identifying Novel Molecular Targets in Growth and Survival Pathways"],"prefix":"10.1182","volume":"2007","author":[{"given":"Owen A.","family":"O\u2019Connor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111707352543100_R1","doi-asserted-by":"crossref","unstructured":"Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995;85:1075\u20131082.","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"2019111707352543100_R2","doi-asserted-by":"crossref","unstructured":"Bertoni F, Ponzoni M. The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol. 2007; 39:1747\u20131753.","DOI":"10.1016\/j.biocel.2007.04.026"},{"key":"2019111707352543100_R3","doi-asserted-by":"crossref","unstructured":"Palutke M, Eisenberg L, Mirchandani I, Tabaczka P, Husain M. Malignant lymphoma of small cleaved lymphocytes of the follicular mantle zone. Blood. 1982;59:317\u2013322.","DOI":"10.1182\/blood.V59.2.317.bloodjournal592317"},{"key":"2019111707352543100_R4","doi-asserted-by":"crossref","unstructured":"Weisenburger DD, Kim H, Rappaport H. Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma. Cancer. 1982;49:1429\u20131438.","DOI":"10.1002\/1097-0142(19820401)49:7<1429::AID-CNCR2820490720>3.0.CO;2-5"},{"key":"2019111707352543100_R5","doi-asserted-by":"crossref","unstructured":"Raffeld M, Jaffe ES. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood. 1991;78:259\u2013263.","DOI":"10.1182\/blood.V78.2.259.259"},{"key":"2019111707352543100_R6","doi-asserted-by":"crossref","unstructured":"Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24:1770\u20131783.","DOI":"10.1200\/JCO.2005.03.7689"},{"key":"2019111707352543100_R7","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185\u2013197.","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"2019111707352543100_R8","doi-asserted-by":"crossref","unstructured":"Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1\u2013negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106:4315\u20134321.","DOI":"10.1182\/blood-2005-04-1753"},{"key":"2019111707352543100_R9","doi-asserted-by":"crossref","unstructured":"Wiestner A, Tehrani M, Chiorazzi M, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood. 2007;109:4599\u20134606.","DOI":"10.1182\/blood-2006-08-039859"},{"key":"2019111707352543100_R10","doi-asserted-by":"crossref","unstructured":"Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25:1620\u20131628.","DOI":"10.1038\/sj.onc.1209371"},{"key":"2019111707352543100_R11","unstructured":"Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005\u20131011."},{"key":"2019111707352543100_R12","doi-asserted-by":"crossref","unstructured":"Hosokawa Y, Gadd M, Smith AP, Koerner FC, Schmidt EV, Arnold A. Cyclin D1 (PRAD1) alternative transcript b: full-length cDNA cloning and expression in breast cancers. Cancer Lett. 1997;113:123\u2013130.","DOI":"10.1016\/S0304-3835(97)04605-3"},{"key":"2019111707352543100_R13","doi-asserted-by":"crossref","unstructured":"Hosokawa Y, Tu T, Tahara H, Smith AP, Arnold A. Absence of cyclin D1\/PRAD1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphism. Cancer Lett. 1995;93:165\u2013170.","DOI":"10.1016\/0304-3835(95)03805-7"},{"key":"2019111707352543100_R14","doi-asserted-by":"crossref","unstructured":"Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem. 2003;278:30339\u201330347.","DOI":"10.1074\/jbc.M303969200"},{"key":"2019111707352543100_R15","doi-asserted-by":"crossref","unstructured":"Burd CJ, Petre CE, Morey LM, et al. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A. 2006;103:2190\u20132195.","DOI":"10.1073\/pnas.0506281103"},{"key":"2019111707352543100_R16","doi-asserted-by":"crossref","unstructured":"Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13:2124\u20132130.","DOI":"10.1002\/j.1460-2075.1994.tb06488.x"},{"key":"2019111707352543100_R17","doi-asserted-by":"crossref","unstructured":"Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1\/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13:3487\u20133495.","DOI":"10.1002\/j.1460-2075.1994.tb06655.x"},{"key":"2019111707352543100_R18","doi-asserted-by":"crossref","unstructured":"Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000;95:619\u2013626.","DOI":"10.1182\/blood.V95.2.619"},{"key":"2019111707352543100_R19","doi-asserted-by":"crossref","unstructured":"Lim MS, Adamson A, Lin Z, et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood. 2002;100:2950\u20132956.","DOI":"10.1182\/blood.V100.8.2950"},{"key":"2019111707352543100_R20","doi-asserted-by":"crossref","unstructured":"Lwin T, Hazlehurst LA, Dessureault S, et al. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle cell and other non-Hodgkin\u2019s B-cell lymphomas. Blood. 2007;110:1631\u20131638.","DOI":"10.1182\/blood-2006-11-060350"},{"key":"2019111707352543100_R21","doi-asserted-by":"crossref","unstructured":"Shuai XM, Han GX, Wang GB, Chen JH. Cyclin D1 antisense oligodexoyneucleotides inhibits growth and enhances chemosensitivity in gastric carcinoma cells. World J Gastroenterol. 2006;12:1766\u20131769.","DOI":"10.3748\/wjg.v12.i11.1766"},{"key":"2019111707352543100_R22","doi-asserted-by":"crossref","unstructured":"McAleer MF, Duffy KT, Davidson WR, et al. Antisense inhibition of cyclin D1 expression is equivalent to flavopiridol for radiosensitization of zebrafish embryos. Int J Radiat Oncol Biol Phys. 2006;66:546\u2013551.","DOI":"10.1016\/j.ijrobp.2006.05.040"},{"key":"2019111707352543100_R23","doi-asserted-by":"crossref","unstructured":"Kawamata N, Chen J, Koeffler HP. SAHA (vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood. 2007;110:2667\u20132673.","DOI":"10.1182\/blood-2005-11-026344"},{"key":"2019111707352543100_R24","doi-asserted-by":"crossref","unstructured":"Venkataraman G, Maududi T, Ozpuyan F, et al. Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment. Leuk Res. 2006;30:1377\u20131384.","DOI":"10.1016\/j.leukres.2006.03.004"},{"key":"2019111707352543100_R25","doi-asserted-by":"crossref","unstructured":"Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005;11:4176\u20134181.","DOI":"10.1158\/1078-0432.CCR-04-2276"},{"key":"2019111707352543100_R26","doi-asserted-by":"crossref","unstructured":"Bogner C, Ringshausen I, Schneller F, et al. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells. Br J Haematol. 2003;122:260\u2013268.","DOI":"10.1046\/j.1365-2141.2003.04438.x"},{"key":"2019111707352543100_R27","doi-asserted-by":"crossref","unstructured":"Hofmann WK, de Vos S, Tsukasaki K, et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood. 2001;98:787\u2013794.","DOI":"10.1182\/blood.V98.3.787"},{"key":"2019111707352543100_R28","doi-asserted-by":"crossref","unstructured":"Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res. 2007;67:2908\u20132911.","DOI":"10.1158\/0008-5472.CAN-07-0082"},{"key":"2019111707352543100_R29","doi-asserted-by":"crossref","unstructured":"Degterev A, Lugovskoy A, Cardone M, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol. 2001;3:173\u2013182.","DOI":"10.1038\/35055085"},{"key":"2019111707352543100_R30","unstructured":"Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin\u2019s lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res. 2000;6:2492\u20132500."},{"key":"2019111707352543100_R31","doi-asserted-by":"crossref","unstructured":"Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002;2:183\u2013192.","DOI":"10.1016\/S1535-6108(02)00127-7"},{"key":"2019111707352543100_R32","doi-asserted-by":"crossref","unstructured":"Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351\u2013365.","DOI":"10.1016\/j.ccr.2006.03.027"},{"key":"2019111707352543100_R33","doi-asserted-by":"crossref","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677\u2013681.","DOI":"10.1038\/nature03579"},{"key":"2019111707352543100_R34","doi-asserted-by":"crossref","unstructured":"Shoemaker AR, Oleksijew A, Bauch J, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res. 2006;66:8731\u20138739.","DOI":"10.1158\/0008-5472.CAN-06-0367"},{"key":"2019111707352543100_R35","doi-asserted-by":"crossref","unstructured":"Marshansky V, Wang X, Bertrand R, et al. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol. 2001;166:3130\u20133142.","DOI":"10.4049\/jimmunol.166.5.3130"},{"key":"2019111707352543100_R36","unstructured":"O\u2019Connor O, SS, Hernandez F, Smith E, Toner L, Czuczman M, Chanan-Khan A. Oblimersen (Bcl-2 antisense) enhances the antitumor activity of bortezomib (Bor) in multiple myeloma (MM) and non-Hodgkin\u2019s lymphoma (NHL) preclinical models [abstract]. Blood. 2003;102: abstract no. 628."},{"key":"2019111707352543100_R37","unstructured":"Paoluzzi L, Gonen M, Toner L, et al. Targeting antiapoptotic BcL-2 family members with AT-101 in pre-clinical models of aggressive lymphoma in combination with cyclophosphamide (C) and rituximab (R) produces a marked improvement in therapeutic efficacy [abstract]. Blood. 2005;106: Abstract no. 926."},{"key":"2019111707352543100_R38","doi-asserted-by":"crossref","unstructured":"Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood. 2007; 109:4441\u20134449.","DOI":"10.1182\/blood-2006-07-034173"},{"key":"2019111707352543100_R39","doi-asserted-by":"crossref","unstructured":"Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta. 2000;1470:M21\u2013M35.","DOI":"10.1016\/S0304-419X(99)00032-3"},{"key":"2019111707352543100_R40","doi-asserted-by":"crossref","unstructured":"Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347\u20135356.","DOI":"10.1200\/JCO.2005.13.466"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/270\/646276\/270_276ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/270\/646276\/270_276ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T12:35:41Z","timestamp":1573994141000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2007\/1\/270\/19193\/Mantle-Cell-Lymphoma-Identifying-Novel-Molecular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2007.1.270","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}